FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W148262973> ?p ?o ?g. }

• W148262973 endingPage "2097" @default.
• W148262973 startingPage "2091" @default.
• W148262973 abstract "Although central nervous system (CNS) leukemic relapse is frequent in adult acute lymphocytic leukemia (ALL), the need for prophylaxis in different risk groups for CNS relapse, the value of high-dose systemic and intrathecal (IT) chemotherapy, and the timing of prophylaxis are not well defined. This analysis was conducted to investigate these questions and to assess the value of a risk-oriented CNS prophylaxis approach. We analyzed the incidence of CNS leukemia after initiation of therapy in patients treated on 4 consecutive trials for adult ALL including different CNS prophylactic modalities. The treatment groups included (1) the program preceeding the vincristine-Adriamycin- dexamethasone (VAD) regimen, with no CNS prophylaxis; (2) the VAD regimen with prophylaxis using high-dose systemic chemotherapy; (3) the modified VAD program with high-dose systemic chemotherapy to all patients and IT chemotherapy for high-risk patients after achieving complete remission; and (4) the hyperCVAD program with early high-dose systemic and IT chemotherapy starting during induction to all patients, with more IT injections (16IT) administered to the high-risk group for CNS relapse compared with the low-risk group (4IT). A total of 391 patients were included, 73 of whom were treated with preVAD, 112 with VAD, 114 with modified VAD, and 92 with hyperCVAD. The overall CNS relapse rates were 31%, 18%, 17%, and 3%, respectively for the 4 groups (P < .001). For the high-risk group for CNS relapse, they were 42%, 26%, 20%, and 2%, respectively (P < .001). The differences in CNS relapse rates in the low-risk group were not statistically significant. At 3 years, the overall CNS leukemia event-free rates were 48%, 76%, and 98%, respectively (P < .001). In the high-risk group, the CNS event- free rates were 38%, 66%, 75%, and 98%, respectively (P < .001); however, there was no difference in the low-risk group. We conclude that (1) high-dose systemic chemotherapy is a useful prophylactic measure; (2) early IT chemotherapy is necessary to reduce the incidence of CNS leukemia overall and in the high-risk group; and (3) a risk- oriented approach is appropriate to tailor the intensity of CNS prophylaxis." @default.
• W148262973 created "2016-06-24" @default.
• W148262973 creator A5006104041 @default.
• W148262973 creator A5015140142 @default.
• W148262973 creator A5027575595 @default.
• W148262973 creator A5030500582 @default.
• W148262973 creator A5038302480 @default.
• W148262973 creator A5090435894 @default.
• W148262973 date "1995-09-15" @default.
• W148262973 modified "2023-10-12" @default.
• W148262973 title "The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia" @default.
• W148262973 cites W121090805 @default.
• W148262973 cites W1483508644 @default.
• W148262973 cites W1563811194 @default.
• W148262973 cites W1580788756 @default.
• W148262973 cites W1589458972 @default.
• W148262973 cites W1834314364 @default.
• W148262973 cites W186939728 @default.
• W148262973 cites W1917409789 @default.
• W148262973 cites W1931698261 @default.
• W148262973 cites W1979300931 @default.
• W148262973 cites W1981552257 @default.
• W148262973 cites W1986023479 @default.
• W148262973 cites W1994704767 @default.
• W148262973 cites W1994718483 @default.
• W148262973 cites W2013324152 @default.
• W148262973 cites W2018413926 @default.
• W148262973 cites W2034252566 @default.
• W148262973 cites W2034569729 @default.
• W148262973 cites W2035073981 @default.
• W148262973 cites W2038701282 @default.
• W148262973 cites W2055132182 @default.
• W148262973 cites W2058194384 @default.
• W148262973 cites W2061482861 @default.
• W148262973 cites W2095242703 @default.
• W148262973 cites W2180813806 @default.
• W148262973 cites W2252957150 @default.
• W148262973 cites W2285218518 @default.
• W148262973 cites W2424624379 @default.
• W148262973 cites W2467334241 @default.
• W148262973 cites W3041375425 @default.
• W148262973 cites W313526845 @default.
• W148262973 doi "https://doi.org/10.1182/blood.v86.6.2091.bloodjournal8662091" @default.
• W148262973 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7662956" @default.
• W148262973 hasPublicationYear "1995" @default.
• W148262973 type Work @default.
• W148262973 sameAs 148262973 @default.
• W148262973 citedByCount "161" @default.
• W148262973 countsByYear W1482629732012 @default.
• W148262973 countsByYear W1482629732013 @default.
• W148262973 countsByYear W1482629732014 @default.
• W148262973 countsByYear W1482629732015 @default.
• W148262973 countsByYear W1482629732016 @default.
• W148262973 countsByYear W1482629732017 @default.
• W148262973 countsByYear W1482629732018 @default.
• W148262973 countsByYear W1482629732019 @default.
• W148262973 countsByYear W1482629732020 @default.
• W148262973 countsByYear W1482629732021 @default.
• W148262973 countsByYear W1482629732022 @default.
• W148262973 countsByYear W1482629732023 @default.
• W148262973 crossrefType "journal-article" @default.
• W148262973 hasAuthorship W148262973A5006104041 @default.
• W148262973 hasAuthorship W148262973A5015140142 @default.
• W148262973 hasAuthorship W148262973A5027575595 @default.
• W148262973 hasAuthorship W148262973A5030500582 @default.
• W148262973 hasAuthorship W148262973A5038302480 @default.
• W148262973 hasAuthorship W148262973A5090435894 @default.
• W148262973 hasBestOaLocation W1482629731 @default.
• W148262973 hasConcept C126322002 @default.
• W148262973 hasConcept C141071460 @default.
• W148262973 hasConcept C143998085 @default.
• W148262973 hasConcept C2776694085 @default.
• W148262973 hasConcept C2776755627 @default.
• W148262973 hasConcept C2778336483 @default.
• W148262973 hasConcept C2778461978 @default.
• W148262973 hasConcept C2779429289 @default.
• W148262973 hasConcept C2781107101 @default.
• W148262973 hasConcept C2781413609 @default.
• W148262973 hasConcept C2909962599 @default.
• W148262973 hasConcept C71924100 @default.
• W148262973 hasConceptScore W148262973C126322002 @default.
• W148262973 hasConceptScore W148262973C141071460 @default.
• W148262973 hasConceptScore W148262973C143998085 @default.
• W148262973 hasConceptScore W148262973C2776694085 @default.
• W148262973 hasConceptScore W148262973C2776755627 @default.
• W148262973 hasConceptScore W148262973C2778336483 @default.
• W148262973 hasConceptScore W148262973C2778461978 @default.
• W148262973 hasConceptScore W148262973C2779429289 @default.
• W148262973 hasConceptScore W148262973C2781107101 @default.
• W148262973 hasConceptScore W148262973C2781413609 @default.
• W148262973 hasConceptScore W148262973C2909962599 @default.
• W148262973 hasConceptScore W148262973C71924100 @default.
• W148262973 hasIssue "6" @default.
• W148262973 hasLocation W1482629731 @default.
• W148262973 hasOpenAccess W148262973 @default.
• W148262973 hasPrimaryLocation W1482629731 @default.
• W148262973 hasRelatedWork W1896861650 @default.
• W148262973 hasRelatedWork W1996462672 @default.

• next